‘ A greater than 50% reduction in palpable spleen length at 24 weeks and at any time on the study was achieved in 62% and 71% of the evaluable patients, respectively. Among patients who achieved a >50% reduction in spleen length at 24 weeks, 95% had maintained this at 48 weeks. Notably, improvements in bone marrow reticulin fibrosis grade occurred in 57% of the patients at 24 months’
Written by
Paul123456
To view profiles and participate in discussions please or .
Combo therapies are an interesting new development, the science is way beyond my pay grade but Ruxo’s anti inflammatory properties make some drugs more tolerable plus it appears to enhance efficacy of combining drug.
The difference between new drugs in trial now versus 10 years ago is very encouraging.........
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.